Eicosapentaenoic acid/metformin
Alternative Names: Eicosapentaenoate/metformin; Metformin/eicosapentaenoate; Metformin/eicosapentaenoic acid; TP-101Latest Information Update: 22 Mar 2016
At a glance
- Originator Thetis Pharmaceuticals
- Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Eicosanoids; Omega 3 fatty acids; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypertriglyceridaemia; Type 2 diabetes mellitus
Most Recent Events
- 22 Mar 2016 No recent reports on development identified - Phase-I for Hypertriglyceridaemia (In volunteers) in USA (PO)
- 22 Mar 2016 No recent reports on development identified - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO)
- 01 Jul 2014 Discontinued - Phase-I for Hypertriglyceridaemia (In volunteers) in USA (PO) (NCT02113163)